Le Lézard
Classified in: Health, Science and technology
Subject: ATY

PRIVACY ALERT: City of Hope Under Investigation for Data Breach of 827,000 Patient Records


SAN FRANCISCO, April 12, 2024 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating a data breach impacting the sensitive personal, financial, and health information of over 827,000 patients of City of Hope National Medical Center, a California-based cancer treatment and research organization.

According to the company, an unauthorized third party accessed a subset of City of Hope's computer systems between September 19 and October 12, 2023 and copied files. The company claims to have first learned of the data breach on October 13, 2023, but only notified some affected patients more than five months later, around April 2, 2024, which may have violated state and federal laws.

The company recently informed patients that the following personal, financial, and health information may have been stolen in the breach: names, email addresses, phone numbers, dates of birth, Social Security numbers, driver's licenses or other government identifications, financial details such as bank account numbers and credit card information, health insurance information, and medical records and medical histories, including medical conditions.

If your personal information was impacted by this incident, you may be at risk of identity theft, healthcare or financial fraud, and other serious violations of your privacy. As a result, you may be entitled to money damages and an injunction requiring changes to City of Hope's cybersecurity practices.

If you received notification of this data breach or are a patient of City of Hope and want additional information about your legal rights, please contact us today or visit our website at https://www.classactionlawyers.com/cityofhope.

About Schubert Jonckheer & Kolbe LLP
Schubert Jonckheer & Kolbe represents shareholders, employees, and consumers in class actions against corporate defendants, as well as shareholders in derivative actions against their officers and directors. The firm is based in San Francisco, and with the help of co-counsel, litigates cases nationwide.

Contact
Dustin L. Schubert
Schubert Jonckheer & Kolbe LLP
[email protected]
Tel: 415-788-4220

SOURCE Schubert Jonckheer & Kolbe LLP


These press releases may also interest you

at 02:15
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...

at 02:05
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and Maze Therapeutics, Inc. (Head Office: South San Francisco, California, USA; Chief Executive Officer: Jason Coloma, Ph.D.;...

at 02:00
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwardsProvides Novavax with cash and an equity investment totalling approximately $1.2 billion...

at 01:00
Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 12, 2024
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders'...

at 00:16
WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval
WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA...

at 00:00
SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer
SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101...

More news about Health...


News published on and distributed by: